JP2004532229A - 脂肪酸アミド加水分解酵素阻害剤 - Google Patents

脂肪酸アミド加水分解酵素阻害剤 Download PDF

Info

Publication number
JP2004532229A
JP2004532229A JP2002584915A JP2002584915A JP2004532229A JP 2004532229 A JP2004532229 A JP 2004532229A JP 2002584915 A JP2002584915 A JP 2002584915A JP 2002584915 A JP2002584915 A JP 2002584915A JP 2004532229 A JP2004532229 A JP 2004532229A
Authority
JP
Japan
Prior art keywords
methyl
imidazol
diphenyl
carbamic acid
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002584915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532229A5 (https=
Inventor
シン−ユエン・シット
シェ・カイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2004532229A publication Critical patent/JP2004532229A/ja
Publication of JP2004532229A5 publication Critical patent/JP2004532229A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002584915A 2001-04-27 2002-04-23 脂肪酸アミド加水分解酵素阻害剤 Pending JP2004532229A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28682701P 2001-04-27 2001-04-27
PCT/US2002/012853 WO2002087569A1 (en) 2001-04-27 2002-04-23 Bisarylimidazolyl fatty acid amide hydrolase inhibitors

Publications (2)

Publication Number Publication Date
JP2004532229A true JP2004532229A (ja) 2004-10-21
JP2004532229A5 JP2004532229A5 (https=) 2005-12-22

Family

ID=23100337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002584915A Pending JP2004532229A (ja) 2001-04-27 2002-04-23 脂肪酸アミド加水分解酵素阻害剤

Country Status (7)

Country Link
US (2) US6562846B2 (https=)
EP (1) EP1389107A4 (https=)
JP (1) JP2004532229A (https=)
CA (1) CA2445294A1 (https=)
IL (1) IL158300A0 (https=)
MX (1) MXPA03009850A (https=)
WO (1) WO2002087569A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511484A (ja) * 2002-10-07 2006-04-06 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア アナンダミド加水分解の遮断による不安の調節
JP2006517218A (ja) * 2003-01-23 2006-07-20 サノフィ−アベンティス アリールアルキルカルバメート誘導体の製造およびそれらの治療用途
JP2007522111A (ja) * 2004-01-16 2007-08-09 サノフイ−アベンテイス アリールオキシアルキルカルバメート型誘導体、これらの調製方法及び治療における該誘導体の使用

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2442330A1 (en) * 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US6949574B2 (en) * 2002-02-08 2005-09-27 Bristol-Myers Squibb Company (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
FR2866886B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
FR2866885B1 (fr) 2004-02-26 2007-08-31 Sanofi Synthelabo Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
EP1742626A2 (en) * 2004-04-23 2007-01-17 The Regents of The University of California Compounds and methods for treating non-inflammatory pain using pparalpha agonists
WO2006044617A1 (en) 2004-10-15 2006-04-27 The Scripps Research Institute Oxadiazole ketone inhibitors of fatty acid amide hydrolase
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
NZ590148A (en) 2004-12-30 2012-04-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
ZA200709038B (en) * 2005-04-13 2009-01-28 Neuraxon Inc Substituted indole compounds having nos inhibitory activity
WO2006116773A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of California Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
EP1983994B1 (en) 2006-02-17 2015-09-30 The Scripps Research Institute Oxazole ketones as modulators of fatty acid amide hydrolase
KR100753240B1 (ko) 2006-03-10 2007-08-30 한국지질자원연구원 합금 나노분말의 제조방법
CA2702468A1 (en) 2007-10-12 2009-04-23 University Of Connecticut Therapeutic applications of fatty acid amide hydrolase inhibitors
EP2062578A1 (en) * 2007-11-12 2009-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel use of chemical compounds for the treatment of AIDS
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
EP2254415B1 (en) 2008-02-19 2013-01-23 Janssen Pharmaceutica, N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
WO2010068452A1 (en) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8901111B2 (en) 2009-06-05 2014-12-02 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
US8735406B2 (en) 2009-09-09 2014-05-27 Dainippon Sumitomo Pharma Co., Ltd. 8-oxodihydropurine derivative
US20120225097A1 (en) 2009-11-12 2012-09-06 Hawryluk Natalie A Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
DE102012018115A1 (de) 2012-09-13 2014-03-13 Matthias Lehr Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase
EP2931291B1 (en) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
DE102013016573A1 (de) 2013-10-04 2015-04-09 Matthias Lehr 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake
CN111269083B (zh) * 2020-02-24 2023-08-25 珠海市柏瑞医药科技有限公司 一种格尔伯特酸的合成方法
US11999703B1 (en) 2023-10-25 2024-06-04 King Faisal University 5-(2,4,5-tris(4-chlorophenyl)-1H-imidazol-1-yl)pentanoic acid as an antimicrobial compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO893909L (no) * 1988-10-03 1990-04-04 Glaxo Group Ltd Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater.
ATE193290T1 (de) * 1992-02-11 2000-06-15 Smithkline Beecham Corp Coa-it- und paf-inhibitoren
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511484A (ja) * 2002-10-07 2006-04-06 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア アナンダミド加水分解の遮断による不安の調節
JP2006517218A (ja) * 2003-01-23 2006-07-20 サノフィ−アベンティス アリールアルキルカルバメート誘導体の製造およびそれらの治療用途
JP2007522111A (ja) * 2004-01-16 2007-08-09 サノフイ−アベンテイス アリールオキシアルキルカルバメート型誘導体、これらの調製方法及び治療における該誘導体の使用

Also Published As

Publication number Publication date
US6562846B2 (en) 2003-05-13
EP1389107A1 (en) 2004-02-18
EP1389107A4 (en) 2005-10-12
USRE39634E1 (en) 2007-05-15
MXPA03009850A (es) 2004-02-12
US20020188009A1 (en) 2002-12-12
IL158300A0 (en) 2004-05-12
CA2445294A1 (en) 2002-11-07
WO2002087569A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
JP2004532229A (ja) 脂肪酸アミド加水分解酵素阻害剤
JP3894949B2 (ja) 抗アテローム性動脈硬化症ジアリール化合物
KR102662215B1 (ko) 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
JP2802547B2 (ja) 抗炎症剤としてのイソキサゾリン化合物
RU2341515C2 (ru) Ацетиленовые производные, способ их получения, фармацевтическая композиция на их основе и их применение в качестве антагонистов метаботропных глутаматных рецепторов (mglur5)
JP5342451B2 (ja) Ｐｄｅ４阻害剤として有用な置換アセトフェノン
JPH03500885A (ja) ロイコトリエンｄ４の拮抗薬としてのキノリン誘導体
US8124778B2 (en) Tricyclic inhibitors of fatty acid amide hydrolase
JPH08109169A (ja) 非ペプチドタキキニン受容体拮抗物質
EP0833822A1 (fr) Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
KR20070116633A (ko) 피지디2 길항제 활성을 갖는 1-아세틱 애시드-인돌 유도체
JPS63246372A (ja) ３−ヘテロ置換−ｎ−ベンジル−インドール
JP6950534B2 (ja) テトラヒドロナフタレン誘導体
EP0934290A1 (fr) Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
EP0984960B1 (fr) N-triazolyl-2-indolecarboxamides et leur utilisation comme agonistes de cck-a
EP1140784A2 (en) Ion channel modulating agents
EP0433149A2 (fr) Antagonistes de la sérotonine, leur préparation et les médicaments les contenant
EP1241168A1 (fr) Composés antagonistes sélectifs du récepteur NK3 humain, procédé pour leur obtention et compositions pharmaceutiques les contenant
JPH09501650A (ja) 治療薬としてのイミダゾール誘導体
KR20010041812A (ko) 비트로넥틴 수용체 길항제
AU631482B2 (en) Improvements in and relating to leukotriene antagonists
JPH0383979A (ja) 新規ベンゾピランおよびベンゾチオピラン誘導体
EP0620221A1 (fr) 5-Acylamino 1,2,4-thiadiazoles comme antagonistes ou agonistes de la cholécystokinine
KR20050106421A (ko) 카르복실산 화합물
US4849434A (en) Novel thiazolidin-4-one derivatives and acid addition salts therof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090217